
BVAC-C Vaccine Therapy Plus Durvalumab Elicits Responses in Recurrent HPV+ Cervical Cancer
Durvalumab (Imfinzi) plus BVAC-C demonstrated durable antitumor activity in patients with human papillomavirus (HPV)–positive cervical cancer who had progressed on first-line platinum-based chemotherapy, according to findings from the single-arm phase 2 …